210 related articles for article (PubMed ID: 21473814)
21. Telemedicine for the Medicare population: pediatric, obstetric, and clinician-indirect home interventions.
Hersh WR; Wallace JA; Patterson PK; Shapiro SE; Kraemer DF; Eilers GM; Chan BK; Greenlick MR; Helfand M
Evid Rep Technol Assess (Summ); 2001 Aug; (24 Suppl):1-32. PubMed ID: 11569328
[TBL] [Abstract][Full Text] [Related]
22. Coverage with Evidence Development: applications and issues.
Trueman P; Grainger DL; Downs KE
Int J Technol Assess Health Care; 2010 Jan; 26(1):79-85. PubMed ID: 20059784
[TBL] [Abstract][Full Text] [Related]
23. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
[TBL] [Abstract][Full Text] [Related]
24. Special funding schemes for innovative medical devices in French hospitals: the pros and cons of two different approaches.
Martelli N; van den Brink H
Health Policy; 2014 Jul; 117(1):1-5. PubMed ID: 24794738
[TBL] [Abstract][Full Text] [Related]
25. Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges.
Federici C; Reckers-Droog V; Ciani O; Dams F; Grigore B; Kaló Z; Kovács S; Shatrov K; Brouwer W; Drummond M
Eur J Health Econ; 2021 Nov; 22(8):1253-1273. PubMed ID: 34117987
[TBL] [Abstract][Full Text] [Related]
26. Health technology assessment and primary data collection for reducing uncertainty in decision making.
Goeree R; Levin L; Chandra K; Bowen JM; Blackhouse G; Tarride JE; Burke N; Bischof M; Xie F; O'Reilly D
J Am Coll Radiol; 2009 May; 6(5):332-42. PubMed ID: 19394574
[TBL] [Abstract][Full Text] [Related]
27. Health technology assessment: a comprehensive framework for evidence-based recommendations in Ontario.
Johnson AP; Sikich NJ; Evans G; Evans W; Giacomini M; Glendining M; Krahn M; Levin L; Oh P; Perera C
Int J Technol Assess Health Care; 2009 Apr; 25(2):141-50. PubMed ID: 19366496
[TBL] [Abstract][Full Text] [Related]
28. DECISION-MAKING ALIGNED WITH RAPID-CYCLE EVALUATION IN HEALTH CARE.
Schneeweiss S; Shrank WH; Ruhl M; Maclure M
Int J Technol Assess Health Care; 2015 Jan; 31(4):214-22. PubMed ID: 26585440
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
Andronis L; Barton P; Bryan S
Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
[TBL] [Abstract][Full Text] [Related]
30. New Metrics for Economic Evaluation in the Presence of Heterogeneity: Focusing on Evaluating Policy Alternatives Rather than Treatment Alternatives.
Kim DD; Basu A
Med Decis Making; 2017 Nov; 37(8):930-941. PubMed ID: 28441507
[TBL] [Abstract][Full Text] [Related]
31. Community Guide Cardiovascular Disease Economic Reviews: Tailoring Methods to Ensure Utility of Findings.
Chattopadhyay SK; Jacob V; Mercer SL; Hopkins DP; Elder RW; Jones CD;
Am J Prev Med; 2017 Dec; 53(6S2):S155-S163. PubMed ID: 29153116
[TBL] [Abstract][Full Text] [Related]
32. Defining the scope of health technology assessment and types of health economic evaluation.
Tanvejsilp P; Ngorsuraches S
J Med Assoc Thai; 2014 May; 97 Suppl 5():S10-6. PubMed ID: 24964694
[TBL] [Abstract][Full Text] [Related]
33. Conditionally funded field evaluations: PATHs coverage with evidence development program for Ontario.
Goeree R; Chandra K; Tarride JE; O'Reilly D; Xie F; Bowen J; Blackhouse G; Hopkins R
Value Health; 2010 Jun; 13 Suppl 1():S8-11. PubMed ID: 20618796
[No Abstract] [Full Text] [Related]
34. Health system and equity perspectives in health technology assessment.
Hanvoravongchai P
J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S74-87. PubMed ID: 19253490
[TBL] [Abstract][Full Text] [Related]
35. Piloting the development of a cost-effective evidence-informed clinical pathway: managing hypertension in Jordanian primary care.
Chalkidou K; Lord J; Obeidat NA; Alabbadi IA; Stanley AG; Bader R; Momani A; O'Mahony RM; Qatami L; Cutler D
Int J Technol Assess Health Care; 2011 Apr; 27(2):151-8. PubMed ID: 21473813
[TBL] [Abstract][Full Text] [Related]
36. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
[TBL] [Abstract][Full Text] [Related]
37. Confronting the "gray zones" of technology assessment: evaluating genetic testing services for public insurance coverage in Canada.
Giacomini M; Miller F; Browman G
Int J Technol Assess Health Care; 2003; 19(2):301-16. PubMed ID: 12862188
[TBL] [Abstract][Full Text] [Related]
38. Application of HTA research on policy decision-making.
Youngkong S
J Med Assoc Thai; 2014 May; 97 Suppl 5():S119-26. PubMed ID: 24964709
[TBL] [Abstract][Full Text] [Related]
39. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
[TBL] [Abstract][Full Text] [Related]
40. Coverage With Evidence Development and Managed Entry in the Funding of Personalized Medicine: Practical and Ethical Challenges for Oncology.
Lewis JR; Kerridge I; Lipworth W
J Clin Oncol; 2015 Dec; 33(34):4112-7. PubMed ID: 26460298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
